Philip Morris International (PM)
NYSEConsumer StaplesTobaccoSnapshot 2026-07-07
$187.75+1.62%
Close 2026-07-07 · 1-day change
Reading PM? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track PM free→NYSEConsumer StaplesTobaccoSnapshot 2026-07-07
Reading PM? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track PM free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on smoke-free products. The current thesis state is mixed, as management has shown strong recent financial performance but faces volatility and sector challenges.
The market currently prices PM with a neutral valuation, reflecting a low fragility tier. Expectations are aligned with recent performance, suggesting that the stock is not overly expensive compared to peers.
Management is on track to achieve its organic revenue growth target of 5% to 7% annually, with adjusted diluted EPS growth also meeting targets. However, the earnings quality remains fragile, and there is a moderate risk of missing future guidance.
The long-term thesis hinges on the performance of sector bellwethers like BTI, MO, and TPB, which could influence PM's trajectory. Additionally, management's ability to sustain growth in smoke-free products will be crucial.
Overall, PM's outlook remains intact, but it faces potential risks from sector dynamics and execution quality. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read. However, a $500 million impairment on the Canada affiliate challenges capital allocation for smoke-free products.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Meeting this EPS target would show strong earnings growth and align with management's guidance.
Confirms:Q2 adjusted diluted EPS reported at or above $2.00.
Disproves:Q2 adjusted diluted EPS was below $1.97.
Why it matters: Growth in ZYN shipments signals strong demand and supports overall revenue growth for PMI.
Confirms:ZYN nicotine pouch shipments are over 780 million cans. This shows strong market demand.
Disproves:ZYN shipments fall below 780 million cans, suggesting weaker demand.
Why it matters: Staying in this range shows smart investment in smoke-free products. It helps growth.
Confirms:Capital spending was between $1.4 and $1.6 billion.
Disproves:Capital spending was below $1.4 billion or above $1.6 billion.
Why it matters: Growing faster than this rate shows strong momentum. It backs management's growth plan.
Confirms:Smoke-free product shipment growth reported above 12% year over year.
Disproves:Smoke-free product shipment growth reported below 10% year over year.
Why it matters: Improving revenue growth shows that PMI is gaining traction in its smoke-free products. This is key for long-term success.
Confirms:Q2 organic revenue growth exceeds 20% year over year.
Disproves:Q2 organic revenue growth remains below 16.7% year over year.
Why it matters: Gains in market share show success in the heat-not-burn category. This drives revenue.
Confirms:IQOS market share goes up by more than 1% in key markets. This shows strong acceptance.
Disproves:IQOS market share stays flat or goes down in key markets. This suggests competitive challenges.
Why it matters: New debt could change PMI's financial flexibility. It may also affect costs.
Confirms:Interest expenses rise a lot because of new debt.
Disproves:Interest expenses stay the same or go down even with new debt.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Changes in market share show PMI's position in the growing smoke-free market.
Confirms one read:PMI's smoke-free market share increases by more than 1% in key markets.
Confirms the other:PMI's smoke-free market share decreases by more than 1% in key markets.
Why it matters: Good FDA decisions could boost smoke-free product sales. They would also support the strategy.
Confirms:FDA allows more smoke-free products.
Disproves:The FDA says no to smoke-free product applications.